US Patent 10076554 FGF21-FC fusion proteins for treating metabolic disorders
Patent 10076554 was granted and assigned to Novartis on September, 2018 by the United States Patent and Trademark Office.
All edits
Edits on 4 Apr, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 8 Dec, 2023
Golden AI
Edits made to:
Article (+301 characters)
Article
Patent abstract
The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
Edits on 28 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
100765540
Date of Patent
September 18, 2018
0Patent Application Number
149873380
Date Filed
January 4, 2016
0Patent Primary Examiner
Edits on 22 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
100765540
Date of Patent
September 18, 2018
0Patent Application Number
149873380
Date Filed
January 4, 2016
0Patent Primary Examiner
Edits on 22 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10076554 FGF21-FC fusion proteins for treating metabolic disorders
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10076554
Date of patent
September 18, 2018
Patent application number
14987338
Date Filed
January 4, 2016
Patent primary examiner
Find more entities like US Patent 10076554 FGF21-FC fusion proteins for treating metabolic disorders
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
